We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05549232
Recruitment Status : Recruiting
First Posted : September 22, 2022
Last Update Posted : September 22, 2022
Sponsor:
Information provided by (Responsible Party):
Hemanext

Brief Summary:
The overall objective of this study is to collect preliminary safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with burns and patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.

Condition or disease Intervention/treatment
Hematologic Neoplasms Burns Device: Hypoxic Red Blood Cells

Detailed Description:

The primary objective is to assess hypoxic RBCs safety and tolerance assessment up to 24 hours following the transfusion initiation and overall up to 7 days (+/- 1 day) after the transfusion episode (single transfusion course).

Secondary objectives include the following.

  1. Assessment of pre and post transfusion hemoglobin levels
  2. Assessment of hemoglobin level before the following transfusion, if applicable
  3. Assessment of AEs occurrence:

    i. Up to 7 days (+/- 1 day) post transfusion, in comparison with historical control (including but not limited to infection, deep vein thrombosis, acute respiratory distress syndrome, transfusion-related acute lung injury, transfusion associated circulatory overload, anaphylactic shock, acute hemolytic transfusion reaction).

    ii. Up to the subsequent transfusion episode or up to 28 days (+/- 1 day) after the initial transfusion, whichever comes first.

    iii. From enrollment, up to their subsequent transfusion or 28 days (+/- 1 day) post transfusion, whichever comes first, through the assessment of patient's diary.

  4. Assessment of the vital signs during and up to 15 minutes after the transfusion.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Single Center, Pilot Clinical Investigation of Surgical Bleeding in Burn Patients, and Chronically Transfused Patients With Haematologic Malignancies, Who Are Transfused With Hypoxic Red Blood Cells Manufactured With Hemanext ONE System
Actual Study Start Date : August 24, 2022
Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : May 31, 2023

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Hematologic Malignancies
Subjects requiring chronic transfusions with red blood cells for treatment of a hematologic malignancy will receive 1 transfusion with 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. The subjects will be monitored for all adverse events from Informed Consent through Day 28 or the subsequent standard of care transfusion, whichever occurs first.
Device: Hypoxic Red Blood Cells
Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced

Acute Burn
Subjects requiring transfusion with red blood cells during the excision procedure after an acute burn will receive 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. As the excision treatments require transfusion of more than 2 units of red blood cells, the first 2 units transfused during the procedure will be hypoxic red blood cells. The subjects will be monitored for all adverse events through Day 28.
Device: Hypoxic Red Blood Cells
Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced




Primary Outcome Measures :
  1. Number of participants who experienced an adverse event (all types/grades) within a time frame up to 24 hours following the transfusion and overall up to 7 days (+/- 1 day) after the transfusion. [ Time Frame: 7 days ]

    The type and the grade of each adverse event will be categorized according to:

    • Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020)
    • Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36
    • Local AEs database (for reference)
    • ISO 14155-2020 definitions


Secondary Outcome Measures :
  1. Evolution of the hemoglobin level before and after the transfusion. [ Time Frame: 1 days ]
    The difference in measured hemoglobin (grams/dL) between pre-transfusion and up to 30 minutes post-transfusion.

  2. Calculation of the Hemoglobin increment after transfusion corrected for patient blood volume and hemoglobin dose [ Time Frame: 28 days ]

    The hemoglobin increment from each transfusion will be determined by calculating the difference between the subject's post-transfusion and pre-transfusion hemoglobin (g/dL). It will then be corrected for estimated subject blood volume and the amount of Hb transfused.

    The following equation used for the hemoglobin increment calculation:

    HgB Increment = (Subject's HgB level post-transfusion - Subject's HgB pre-transfusion)/ (total HgB transfused x Subject's BloodVolume)

    Equations for calculating the hemoglobin increment may be found in the following publication: Wendelbo Ø, Opheim EN, Hervig T, Felli Lunde TH, Bruserud Ø, Mollnes TE, Reikvam H. Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. Vox Sang. 2018 Oct;113(7):657-668. doi: 10.1111/vox.12703. Epub 2018 Aug 29. PMID: 30159896.


  3. Comparison of the Hemoglobin level before the index transfusion to that prior to the subsequent transfusion (hematologic malignancy group only) [ Time Frame: 28 days ]
    The difference in measured hemoglobin (grams/dL) between the pre-transfusion hemoglobin level for the study transfusion and the pre-transfusion hemoglobin level for the next scheduled transfusion.

  4. Evaluation of AEs from enrollment, up to prior to the subsequent transfusion or up to Day 28, whichever occurs first [ Time Frame: 28 days ]

    The type and the grade of each adverse event will be categorized according to:

    • Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020)
    • Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36
    • Local AEs database (for reference)
    • ISO 14155-2020 definitions

  5. Evaluation of subject's blood pressure over the course of the transfusion and up to 15 minutes post-transfusion [ Time Frame: 1 day ]
    Review of blood pressure (systolic/diastolic; mmHg) throughout the study transfusion.

  6. Evaluation of subject's respiratory rate over the course of the transfusion and up to 15 minutes post-transfusion [ Time Frame: 1 day ]
    Review of respiratory rate (breaths per minute) throughout the study transfusion.

  7. Evaluation of subject's SO2 level over the course of the transfusion and up to 15 minutes post-transfusion [ Time Frame: 1 day ]
    Review of amount of oxygen in the body (% S02 level) measured with a pulse oximeter throughout the study transfusion.

  8. Evaluation of subject's pulse over the course of the transfusion and up to 15 minutes post-transfusion [ Time Frame: 1 day ]
    Review of heart rate (beats per minute) throughout the study transfusion.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
10 acute burn patients and 10 patients with hematological malignancies, who require transfusion of red cells concentrates and who fulfill all eligibility criteria will be enrolled in this clinical investigation at Haukeland University Hospital.
Criteria

Inclusion Criteria:

A. Hematological malignancies patients group:

  1. Male or female patients at least 18 years of age
  2. Patients expected to require > 2 units of red blood cells in a single transfusion event
  3. Patients who have the capacity to consent to participate and are willing to comply with the study procedures.
  4. Patients identified by a Transfusion hemoglobin trigger of less than 9 g/dL
  5. Patients with a documented diagnosis of leukemia, myelomatosis or MDS requiring chronic transfusions

B. Burn patients group:

  1. Male or female patients at least 18 years of age
  2. Patients who have the capacity to consent by themselves to participate to the clinical investigation
  3. Smaller burn patients, hospitalized with a Total Body Surface Area (TBSA%) burn ≥ 10% and ≤ 50%
  4. Patients expected to require > 2 unit of red blood cells in a single transfusion event

Exclusion Criteria:

A. Both patients groups

  1. Patients with any positive antibody screening test
  2. Patients for whom consent has not been obtained
  3. Patients with a known hemolytic anemia (congenital or acquired)
  4. Patients < 18 years old
  5. Patients with a known or suspected pregnancy
  6. Patients with a history of major transfusion reactions
  7. Patients whom the Investigator deems clinical trial participation is not in their best interest.

B. Burn patients specific exclusion criteria :

  1. Patients who do not have the capacity to consent by themselves to participate to the clinical investigation
  2. Patients hospitalized with a Total body surface area (TBSA%) burn more than 50%
  3. Patients with combined trauma in need of blood transfusions for treatment other than the burn excision

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05549232


Contacts
Layout table for location contacts
Contact: Kimberly Dorsch +1.781.301.7443 kim.dorsch@hemanext.com

Locations
Layout table for location information
Norway
Haukeland University Hospital Recruiting
Bergen, Norway, 5021
Contact: Stian Almeland, MD    +47 55 9750    stian.kreken.almeland@helse-bergen.no   
Sub-Investigator: Hakon Reikvam, MD         
Sponsors and Collaborators
Hemanext
Publications:
Layout table for additonal information
Responsible Party: Hemanext
ClinicalTrials.gov Identifier: NCT05549232    
Other Study ID Numbers: PRO-CLIN-0012
First Posted: September 22, 2022    Key Record Dates
Last Update Posted: September 22, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Hemanext:
Transfusion
Red Blood Cells
Hypoxic
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Neoplasms
Burns
Neoplasms
Wounds and Injuries
Neoplasms by Site
Hematologic Diseases